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Visceral leishmaniasis is a relevant public health problem worldwide. Most of the reported
cases  in Latin America are from Brazil. Herein we report two human cases of congeni-
tally  transmitted visceral leishmaniasis in two patients who developed symptoms during
pregnancy.  The diagnosis was made by visual examination of Leishmania parasites in bone
marrow  aspirates of the mothers and by detecting parasite kDNA in bone marrow samples
of  the newborn children using polymerase chain reaction.ongenital transmission
isceral  leishmaniasis
eishmania infantum
regnancy
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merican visceral leishmaniasis (AVL) is an endemic disease
aused  by Leishmania infantum (syn. L. chagasi), which occurs
redominantly in tropical and subtropical regions of South
merica.  AVL is typically transmitted to humans through the
ite  of the female sand ﬂy Lutzomyia longipalpis. Other routes of
ransmission  have been reported in humans such as sharing of
ontaminated  needles among drug users,1 organ transplants2
3nd congenital transmission. Classic manifestations of AVL
re  persistent fever, weight loss, progressive anemia or
ancytopenia, hypergammaglobulinemia, hepatomegaly and
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Este é um artigo Open Access sob a licençasplenomegaly. Congenital transmission of visceral leishman-
iasis  was  ﬁrst reported by Low and Cooke4 in Africa and by
2011,  nine cases of AVL were reported in pregnant women
in  Brazil.5–8 Congenitally transmitted visceral leishmaniasis
has a course of disease similar to that acquired by the bite
of  sand ﬂies. The majority of children with congenital infec-
tion  present with the illness within the ﬁrst year, but the exact
means  of transmission are not yet completely clear.9–11 Herein
we  describe two cases of AVL among pregnant patients who
transmitted  the disease congenitally to their infants admittededicina Tropical, Universidade de Brasília, Campus Universitário
Romero).
between  Jan 2007 and Dec 2008 to Dona Regina Hospital, which
is  a tertiary referral center for maternal and infant care in the
city  of Palmas, Tocantins, Brazil.
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Fig. 1 – Identiﬁcation of 120 bp of the conserved region of
the Leishmania minicircle-kDNA in bone marrow aspirates
from  newborns using polymerase chain reaction (PCR)
revealed  in 2% agarose gel stained with ethidium bromide.
Lane  1: molecular weight ladder (M); lane 2: empty; lanes 3
and 5: bone marrow from newborns 1 and 2, respectively;
lane 4: negative control (NC) without DNA;  lane 6: positive
control  (PC) consisting of cultured promastigotes of264  b r a z j i n f e c t d 
Pregnancy was  conﬁrmed by serum levels of -human
chorionic gonadotropin hormone and by an abdominal ultra-
sound.  Indirect ﬂuorescent antibody test (IFAT) test was
performed in sera samples to detect antibodies against Leish-
mania,  as recommended by the Brazilian Ministry of Health12;
bone  marrow smears were  stained with Giemsa to detect
the  presence of Leishmania amastigotes; and a genus-speciﬁc
polymerase chain reaction (PCR) was  performed using bone
marrow  samples to detect 120 bp of the conserved region of
parasite  kDNA, as reported elsewhere.13 The bone marrow
aspirates were  obtained from the pregnant women during hos-
pitalization and from the newborns during the ﬁrst week after
their  delivery (Fig. 1).
The  study was  conducted in agreement with the National
Health Council Resolution number 196/96 which regulates
research involving human subjects in Brazil and the Helsinki
Declaration. A conﬁdentiality agreement was  signed by the
researchers  to protect the patient identity upon obtaining
information from their medical records. All patients or their
relatives/legal guardians signed a voluntary and informed
consent  form authorizing the use of their medical records.
Case  presentation
Case  1
A 24-year-old woman  from the city of Itacajá, Tocantins,
who  was  pregnant for the second time, was hospitalized
with fever above 38 ◦C. During the sixth month of pregnancy
she  reported fever and weight loss. A physical examination
revealed mucocutaneous pallor, dyspnea and slight edema in
the lower limbs. Upon review of the abdominal ultrasound
it  was  found a posterior placenta of heterogeneous texture
and  stage I maturity, a 30-week and 4-day gestational age
and  a fetal heart rate of 170 beats/min, with no evidence of
fetal  hepatosplenomegaly. Because of acute fetal distress, the
patient  underwent a cesarean section, resulting in a preterm
Table 1 – Main clinical and laboratory ﬁndings upon hospital ad
with American visceral leishmaniasis in Brazil.
Characteristic Case 1 
On admission 7
post
Axillary temperature (◦C) 38.0 37
Spleen size under left costal margin (cm) 10 8.
Hemoglobin (g/dL) 7.3 5.
Hematocrit (%) 22 27
White blood count (cells/mm3) 2600 60
Platelet count (platelets/mm3) 151,000 12
Prothrombin time (%) 78 63
Total bilirubin (mg/dL) 0.8 9.
Direct bilirubin (mg/dL) 0.5 3.
Plasma albumin (g/dL) 3.8 2.
Plasma globulin (g/dL) 2.6 4.
AST (U/L) 38 17
ALT (U/L) 32 32
BUN (mg/dL) 23 28
Serum creatinine (mg/dL) 0.7 0.Leishmania chagasi (syn. Leishmania infantum).
newborn. The mother presented with productive cough, and
the  chest X-ray revealed basal inﬁltration in the right hemi
thorax.  Antibiotic therapy with intravenous oxacillin and cef-
triaxone were initiated and she received a packed red blood
cell  transfusion. Given the clinical and laboratory evidence
(Table  1), the patient underwent a bone marrow aspiration,
which revealed the presence of Leishmania amastigotes. Thus,
she  was  started on intravenous amphotericin B desoxycholate
1  mg/kg/day. The following day; she had persistent fever,
a  painful surgical wound, jaundice and echimosis on her
abdomen, periorbital region and arms. Then, amphotericin
mission and during treatment of two pregnant women
Case 2
th day
-partum
On admission 7th day
post-partum
14th day
post-partum
.2 38.5 36.2 36.3
5 6 4 4
2 11.0 6.0 9.6
 33 15 28
00 4643 10,200 15,300
2,000 315,000 80,000 155,000
 92 36 58
5 0.4 4.6 6.4
2 0.12 1.1 2.2
2 2.7 2.2 3.0
9 4.2 4.7 4.5
9 15 64 85
7 48 96 113
 32 27 25
9 0.8 0.7 0.8
 2 0 1 
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 desoxycholate was  replaced by an intravenous liposomal
ormulation of amphotericin B, 3 mg/kg/day, and the patient
as  transferred to a critical care unit. The patient developed a
oagulation disorder, generalized bleeding and died 10 days
fter  being hospitalized. IFAT result obtained on admission
as  positive with dilution titer of 160 (reference cut-off = 40).
The newborn female weighed 1170 g and was  classiﬁed
s  extremely premature. Her weight was  appropriate for the
stimated  gestational age, and she had an Apgar score of 6
nd  8 during the ﬁrst and ﬁfth minutes after birth, respec-
ively.  Within the next 24 h, she developed grade II pulmonary
yaline  membrane disease, for which she was  maintained
n  nasal continuous positive airﬂow pressure. Splenomegaly
nd  hepatomegaly were detected on physical examination.
he  following day, the newborn’s tachypnea worsened, and
he  was  placed on mechanical ventilation. In addition, she
as  started on antimicrobial therapy with ampicillin and
mikacin.  After 72 h, the patient developed jaundice and wors-
ning  anemia. Bone marrow aspirate smears looking for the
resence  of Leishmania was  negative. Despite multiple blood
ransfusions, the newborn’s erythrocyte indexes continued to
ecrease. We  then performed a PCR test to detect parasite
DNA  using the cells collected from the bone marrow aspirate
hich  gave a positive result for Leishmania spp. The new-
orn  was  started on treatment with intravenous amphotericin
 deoxycholate, 1 mg/kg/day for 14 days making satisfactory
rogress and being discharged from the critical care unit 20
ays  after birth.
ase  2
 23-year-old woman from the city of Porto Nacional,
ocantins, who  was  pregnant for the second time, was  hos-
italized  with complaint of intermittent fever during the past
 months associated with weakness, fatigue, vomiting and
norexia.  A physical examination of the patient revealed dehy-
ration,  weight loss and edema of the legs. She reported
aving suffered from eclampsia during her previous preg-
ancy,  and she had undergone ﬁve prenatal evaluations
ith no abnormal blood pressure levels. During the seventh
onth  of pregnancy, she presented with daily fever, lower
imb  edema, jaundice and progressive anemia. An ultrasound
est  revealed a slight decrease in amniotic ﬂuid, a poste-
ior  placenta of heterogeneous texture and stage II maturity
onsistent with a 35-week and 4-day gestational age, a fetal
eart  rate of 169 beats/min, splenomegaly and mild right
ydronephrosis. Clinical and laboratory ﬁndings are described
n  Table 1. Because of acute fetal distress, it was  performed a
esarean section and delivered a preterm infant with a weight
hich  was  appropriate for the gestational age. Direct analysis
f  bone marrow smears from the mother revealed the pres-
nce  of Leishmania amastigotes. The mother was treated with
ntravenous  liposomal amphotericin B, 3 mg/kg/day, IV for 7
ays. However, her general condition deteriorated, as indi-
ated  by a worsening of her anemia, dyspnea, toxemia and
ostural  hypotension and decrease of prothrombin activity.
he  patient was  transferred to the intensive care unit where
he  recovered and was  discharged after 14 days. IFAT result
btained  on admission was  positive with dilution titer of 160
reference  cut-off = 40).3;1 7(2):263–266  265
The newborn male weighed 2590 g which was  appropriate
for  the gestational age, and he had an Apgar score of 3 and 5
for  the ﬁrst and ﬁfth minutes of life, respectively. The newborn
developed acute respiratory failure due to meconium aspira-
tion  and required mechanical ventilation. Splenomegaly was
detected  on physical examination. The newborn was  trans-
ferred  to the neonatal intensive care unit and was  treated
with  ampicillin and amikacin, with no clinical improvement.
Suspecting visceral leishmaniasis, we obtained a bone mar-
row  aspirate looking for Leishmania amastigotes but the results
were  negative. Due to severe anemia, he required multiple
blood  transfusions and later, he developed jaundice being
started  on oxacillin and cefepime plus intravenous liposo-
mal  amphotericin B 3 mg/kg/day. A PCR test for Leishmania
kDNA was  positive on bone marrow aspirate. The newborn
had  satisfactory progress and was  discharged 50 days after
birth.
Discussion
The present cases of congenitally acquired visceral leish-
maniasis constitute a rare condition. During 2007 and 2008,
there  were 873 visceral leishmaniasis cases in adults and
children  residents in the State of Tocantins that were  reg-
istered  in the Brazilian National Surveillance System. Most
of  the congenital visceral leishmaniasis infections described
in  the literature follow a course where there are few or no
maternal  symptoms and where macroscopic changes of the
placenta  and its annexes are typically not observed. Also,
it  has not been possible to conﬁrm that transplacental fetal
infection  has been the mode of transmission in any of the
cases  that have been reported so far. Eltoum et al. reported
a  case of a pregnant woman  with symptomatic leishmania-
sis  who suffered a miscarriage.11 The authors proposed that
the  parasite entered into the fetal circulation during its sep-
aration  from the placenta or through damaged areas in the
maternal–fetal barrier because the mother showed no signs
of  illness. In addition, laboratory tests on the aborted fetus
showed  thrombosis, ﬁbrin deposition in a third of the pla-
cental  chorionic villi, the presence of amastigotes inside and
outside  macrophages and the absence of an inﬂammatory
reaction in response to the parasites. Unfortunately, placenta
histopathologic studies were not performed in the present
cases.
In  pregnant women, the detection of visceromegaly can
be  impaired by the growth of the uterus. Among the labora-
tory  studies that pregnant women typically undergo are direct
visualization  of amastigote forms in bone marrow smears
and  detection of anti-Leishmania serum antibodies using the
IFAT,  where the presence of quantiﬁable titers of antibod-
ies  higher than 40-fold dilution of the serum is considered
positive. The PCR is a highly sensitive and speciﬁc tech-
nique  to detect Leishmania kDNA, making it an important
tool to improve the opportunity of early treatment, especially
in  newborns to avoid misinterpretation of positive serolog-
ical  tests due to passive transfer of maternal antibodies.
The tests performed on the two pregnant women  upon their
admission  revealed that they had high titers of antibod-
ies,  which could cross the placental barrier. Although the
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bone marrow smears were  positive for Leishmania amastigotes
in  the pregnant women, they were  not elucidatory in the
newborns.  PCR ampliﬁcation of parasite kDNA in newborn’s
bone  marrow samples suggests that leishmaniasis was  verti-
cally  transmitted because they developed signs of the disease
shortly  after birth and remained in the hospital until their
more  severe symptoms were resolved while on speciﬁc anti-
leishmanial  treatment. The early onset of symptoms after
birth  rules out the possibility that the newborns acquired
the  disease through vector transmission. This result demon-
strates  that, using PCR, it is possible to make an early diagnosis
of  leishmaniasis in the newborn and provide immediate treat-
ment  for the mother and fetus to avoid or minimize disease
complications.
There  is a concern about the effect of the drugs used for
the  treatment of leishmaniasis on the well-being of the fetus
because  clinical trials developed for approval purposes with
drugs  against visceral leishmaniasis usually exclude pregnant
women.  However, a recent study conducted in Africa showed
a  higher incidence of abortion in patients treated with pen-
tavalent  antimony.14 The transplacental transfer of antimony
has  been proved in mice, showing that approximately 1/3 of
the  antimony present in the maternal blood is transferred
to  the fetus.15 The second woman who was  diagnosed ben-
eﬁted  from the experience we gained from the ﬁrst patient
who  died earlier. As a result, she was  treated with liposo-
mal  amphotericin B, which could have contributed to her
favorable  recovery. Because AVL among pregnant women is
an extremely serious health concern it is reasonable to rec-
ommend  treatment with liposomal amphotericin B because
it  has the best safety proﬁle. Monitoring for the presence of
AVL  in pregnant women  living in endemic areas is essential
for  the implementation of timely treatment and can prevent
fatal  outcomes.
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